Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 296

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Aspiration Thrombectomy After Intravenous Alteplase Versus Intravenous Alteplase Alone

Open access
Mocco, J, Zaidat, Osama O., von Kummer, Rüdiger, Yoo, Albert J., Gupta, Rishi, Lopes, Demetrius, Frei, Don, Shownkeen, Harish, Budzik, Ron, Ajani, Zahra A., Grossman, Aaron, Altschul, Dorethea, McDougall, Cameron, Blake, Lindsey, Fitzsimmons, Brian-Fred, Yavagal, Dileep, Terry, John, Farkas, Jeffrey, Lee, Seon Kyu, Baxter, Blaise, Wiesmann, Martin, Knauth, Michael, Heck, Donald, Hussain, Syed, Chiu, David, Alexander, Michael J., Malisch, Timothy, Kirmani, Jawad, Miskolczi, Laszlo, Khatri, Pooja · 2016 · Stroke

Abstract

Background and Purpose—: Thrombectomy, primarily with stent retrievers with or without adjunctive aspiration, provided clinical benefit across multiple prospective randomized trials. Whether this benefit is exclusive to stent retrievers is unclear. Methods—: THERAPY (The Randomized, Concurrent Controlled Trial to Assess the Penumbra System’s Safety and Effectiveness in the Treatment of Acute Stroke; NCT01429350) was an international, multicenter, prospective, randomized (1:1), open label, blinded end point evaluation, concurrent controlled clinical trial of aspiration thrombectomy after intravenous alteplase (IAT) administration compared with intravenous-alteplase alone in patients with large vessel ischemic stroke because of a thrombus length of ≥8 mm. The primary efficacy end point was the percent of patients achieving independence at 90 days (modified Rankin Scale score, 0–2; intention-to-treat analysis). The primary safety end point was the rate of severe adverse events (SAEs) by 90 days (as treated analysis). Patients were randomized 1:1 across 36 centers in 2 countries (United States and Germany). Results—: Enrollment was halted after 108 (55 IAT and 53 intravenous) patients (of 692 planned) because of external evidence of the added benefit of endovascular therapy to intravenous-alteplase alone. Functional independence was achieved in 38% IAT and 30% intravenous intention-to-treat groups ( P =0.52). Intention-to-treat ordinal modified Rankin Scale odds ratio was 1.76 (95% confidence interval, 0.86–3.59; P =0.12) in favor of IAT. Secondary efficacy analyses all demonstrated a consistent direction of effect toward benefit of IAT. No differences in symptomatic intracranial hemorrhage rates (9.3% IAT versus 9.7% intravenous, P =1.0) or 90-day mortality (IAT: 12% versus intravenous: 23.9%, P =0.18) were observed. Conclusions—: THERAPY did not achieve its primary end point in this underpowered sample. Directions of effect for all prespecified outcomes were both internally and externally consistent toward benefit. It is possible that an alternate method of thrombectomy, primary aspiration, will benefit selected patients harboring large vessel occlusions. Further study on this topic is indicated. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01429350.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/strokeaha.116.013372

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 296

Metadata

Authors
Mocco, J., Zaidat, O. O., von Kummer, R., Yoo, A. J., Gupta, R., Lopes, D., Frei, D., Shownkeen, H., Budzik, R., Ajani, Z. A., Grossman, A., Altschul, D., McDougall, C., Blake, L., Fitzsimmons, B.-F., Yavagal, D., Terry, J., Farkas, J., Lee, S. K., Baxter, B., Wiesmann, M., Knauth, M., Heck, D., Hussain, S., Chiu, D., Alexander, M. J., Malisch, T., Kirmani, J., Miskolczi, L., & Khatri, P.
Venue
Stroke
Published
2016-09
Volume
47
Issue
9
Pages
2331-2338
ISSN
  • 0039-2499 (ISSN-L)
  • 1524-4628
OpenAlex
W2475487380
Cited by
296
References
27
FWCI
40.89
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.